Abstract
IBCL-492 A Cost-Effectiveness Analysis of Mosunetuzumab for Treatment of Thirdor Higher-Line Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in the United States (US)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have